Nutriband

At Nutriband and our subsidiaries, our core focus is to use innovative drug delivery systems and devices to improve patient outcomes, specifically targeting the Global Opioid epidemic. Fentanyl and other opioid based transdermal medications unfortunately play a role in a significant number of opioid deaths each year with no solution currently available. Working with our Clinical subsidiary 4P Therapeutics we have developed a technology called AVERSA which we believe with FDA approval will revolutionize the safety standard for these medications and save countless lives per year.